Quoc Hung Tran
Psychiatry · Dallas, TXNPI 1871645556
Payments from drug & device makers
Across 229 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$954
- Otsuka America Pharmaceutical, Inc.$779
- Sunovion Pharmaceuticals Inc.$467
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$457
- Corium, LLC$278
- Vanda Pharmaceuticals Inc.$163
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,121100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $954 |
| Otsuka America Pharmaceutical, Inc. | 37 | $779 |
| Sunovion Pharmaceuticals Inc. | 25 | $467 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $457 |
| Corium, LLC | 14 | $278 |
| Vanda Pharmaceuticals Inc. | 11 | $163 |
| Ironshore Pharmaceuticals Inc. | 8 | $141 |
| Neurocrine Biosciences, Inc. | 8 | $132 |
| Lundbeck LLC | 6 | $126 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Idorsia Pharmaceuticals US Inc | 4 | $76 |
| Brainsway USA Inc | 1 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $51 |
| Noven Therapeutics, LLC | 3 | $51 |
| Neuronetics, Inc. | 2 | $51 |
| Neos Therapeutics, LP | 3 | $46 |
| Shire North American Group Inc | 3 | $40 |
| Johnson & Johnson | 3 | $39 |
| Tris Pharma Inc | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Validus Pharmaceuticals LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Alfasigma USA, Inc. | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$4,121 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 22 | $37,250 |
| Quetiapine Fumarate | 32 | $5,377 |
| Lisdexamfetamine Dimesylate | 17 | $2,529 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,456 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $1,132 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 52 | $913 |
| Alprazolam | 121 | $735 |
| Aripiprazole | 15 | $539 |
| Lamotrigine | 27 | $405 |
| Escitalopram Oxalate | 23 | $372 |
| Bupropion XlBupropion Hcl | 18 | $270 |
| Clonazepam | 48 | $209 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $166 |
| Ondansetron OdtOndansetron | 15 | $159 |
| Sertraline Hcl | 16 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $954 | $37,25022 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $9116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Dallas
- Scott BartleyDallas$42.7M
- Darin OkudaDallas$14.7M
- Michael DowningDallas$7.6M
- John PascoeDallas$2.3M
- Madhukar TrivediDallas$2.1M
- Manish JhaDallas$1.3M
- Mary KnesevichDallas$1.2M
- Seema GuptaDallas$1.2M
- Eric WilliamsDallas$976K
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.